Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer.

Akkermansia muciniphila suppresses macrophage efferocytosis via TLR2/NF-κB, activating immune pathways that enhance anti-PD-1 therapy in MSS colorectal cancer.

• Why it matters: Most colorectal cancers are microsatellite stable and resistant to anti-PD-1 therapy, creating a need for strategies to overcome this resistance and improve treatment outcomes.
• What they did: Researchers administered Akkermansia muciniphila orally in MSS CRC mouse models, observing suppression of tumor growth and reprogramming of the tumor microenvironment through immune pathway modulation.
• The result: The combination of Akk probiotics with PD-1 antibody in patients showed a 19% objective response rate, indicating enhanced antitumor immunity and a promising approach to overcoming immunotherapy resistance.